Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Ubiquinol, the reduced and active antioxidant form of coenzyme Q10 (CoQ10), is used as a supplement to support or treat congestive heart failure (CHF). There is a growing body of scientific evidence supporting its role in heart health, specifically in CHF. CoQ10 is essential for mitochondrial ATP production, and heart muscle cells are particularly reliant on efficient energy metabolism. Research has shown that patients with CHF often have lower levels of CoQ10 in their cardiac tissue and plasma. Supplementation with CoQ10 (including its ubiquinol form) has been studied in several randomized controlled trials. Notably, the Q-SYMBIO trial (2014) demonstrated that long-term CoQ10 supplementation significantly improved symptoms, reduced major adverse cardiovascular events, and decreased mortality in patients with moderate to severe CHF. Ubiquinol, due to its higher bioavailability compared to ubiquinone, may be particularly beneficial in elderly and severely ill patients. Meta-analyses and systematic reviews generally suggest modest improvements in ejection fraction, symptoms (NYHA functional class), and quality of life. However, some trials report only marginal benefits, and routine use is not yet universally recommended in clinical guidelines. Overall, the scientific evidence is promising, especially as an adjunct to standard heart failure therapy, but further large-scale studies are needed to fully establish its efficacy and optimal dosing.

More about ubiquinol
More about Congestive Heart Failure

Other ingredients used for Congestive Heart Failure

Other health conditions supported by ubiquinol

Products containing ubiquinol